Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gibbons

Showing results (311-320 of 470) with videos related to

Pageof 47
Sort By:
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung CancerAmgad Muneer, Eman Showkatian, Yuliya Kitsel, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
Nature Communications|October 17, 2022
A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infectionClara Calvert, Jade Carruthers, Cheryl Denny, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case ReportBingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Cell Reports|September 2, 2023
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophagesChia-Nung Hung, Meizhen Chen, Daniel T DeArmond, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
The Oncologist|May 8, 2023
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center ExperienceMehmet Altan, Felipe Soto, Linda L Zhong, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Pageof 47

Showing results (311-320 of 470) with videos related to

Sort By:
Pageof 47
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung CancerAmgad Muneer, Eman Showkatian, Yuliya Kitsel, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
Nature Communications|October 17, 2022
A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infectionClara Calvert, Jade Carruthers, Cheryl Denny, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case ReportBingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Cell Reports|September 2, 2023
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophagesChia-Nung Hung, Meizhen Chen, Daniel T DeArmond, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
The Oncologist|May 8, 2023
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center ExperienceMehmet Altan, Felipe Soto, Linda L Zhong, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Pageof 47